China Pharmaceutical Sector Report 2019 2nd QuarterAn EMIS Insights Industry Report
EMIS is an ISI Emerging Markets Group Company Date: August 2019
Available in: English
In the first quarter of 2019, China’s pharmaceutical and medicine production declined by 7.2% y/y to 720,000 tonnes, while the sales of pharmaceuticals went down by 3.4% y/y to 700,460 tonnes. The decline in output can be linked to the increasing pressure on pharmaceutical companies, which were forced to lower drug prices via the newly-announced scheme for centralised tendering with guaranteed procurement volume launched at the end of 2018. The prices for the 25 generic drugs that won the bids under the pilot centralised drug procurement scheme declined by an average of 52%, while the largest drop in price was 96%. At the same time, the prices of some APIs in China increased as their cost of production rose in line with the government’s continuous measures to address environmental concerns.
This report provides a complete and detailed analysis of the pharmaceutical sector for China. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.
What this report allows you to do:
- Understand the key elements at play in the pharmaceutical sector in China
- Access forecasts for growth in the sector
- View key data on production and sales for the sector in China
- Crystallise the forces both driving and restraining this sector in China
- Build a complete perspective on sector trade, investment and employment
- Understand the competitive landscape and who the major players are
- View M&A activity and major deals
- Gain an understanding of the regulatory environment for the sector in China
- Build a clear picture of trends and issues for sub-sectors (western medicine, traditional Chinese medicine)